阿斯利康AstraZeneca plc (AZN) 2008年年度报告「LSE」.pdf

1、REGISTERED OFFICE AND CORPORATE HEADQUARTERSAstraZeneca PLC15 Stanhope GateLondon W1K 1LNUKTel:+44(0)20 7304 5000Fax:+44(0)20 7304 5151INVESTOR RELATIONSE-mail:IRUK:as aboveSweden:AstraZeneca ABSE-151 85 SdertljeSwedenTel:+46(0)8 553 260 00Fax:+46(0)8 553 290 00US:Investor RelationsAstraZeneca Pharm

2、aceuticals LP1800 Concord PikePO Box 15437WilmingtonDE 19850-5437USTel:+1(302)886 3000Fax:+1(302)886 2972REGISTRAR AND TRANSFER OFFICEEquiniti Limited Aspect HouseSpencer RoadLancingWest SussexBN99 6DAUKTel(freephone in the UK):0800 389 1580Tel(outside the UK):+44(0)121 415 7033SWEDISH CENTRAL SECUR

3、ITIES DEPOSITORYEuroclear Sweden ABPO Box 7822SE-103 97 StockholmSwedenTel:+46(0)8 402 9000US DEPOSITARYJPMorgan Chase&CoPO Box 64504St PaulMN 55164-0504USTel(toll free in the US):800 990 1135Tel(outside the US):+1(651)453 2128E-mail:ASTRAZENECA.COMThis Annual Report and Form 20-F Information is als

4、o available online at INFORMATIONASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2008ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2008Cautionary statement regarding forward-looking statementsThe purpose of this Annual Report and Form 20-F Information is to provide information to the membe

5、rs of the Company.In order,among other things,to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act 1995 and the UK Companies Act 2006,we are providing the following cautionary statement:This Annual Report and Form 20-F Information contains certain forward-looking

6、 statements with respect to the operations,performance and financial condition of the Group.Although we believe our expectations are based on reasonable assumptions,any forward-looking statements,by their nature,involve risks and uncertainties and may be influenced by factors that could cause actual